All In Biotech

NDA 204677 · Lantheus

Neuraceq

Florbetaben F-18 · Intravenous · Radioactive Diagnostic Agent

Novel

Last checked: Nov 20, 2026Latest source record: Jul 22, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Mar 19, 2014

Approved uses

2

Original approval plus efficacy supplements

Registered trials

30

1 Phase 3, 9 recruiting

FAERS reports

21

5 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 24, 2026.

NEURACEQ is indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for: Evaluation of Alzheimer’s disease (AD) and other causes of cognitive decline Selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products NEURACEQ is a radioactive diagnostic drug indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for: Evaluation of Alzheimer’s disease (AD) and other causes of cognitive decline Selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products (1)

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • NEURACEQ · FLORBETABEN F-18 1.4-135mCi/ML · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Florbetaben F-18" as an intervention, any sponsor and status, largest first.

All 30 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • amyloid related imaging abnormality-oedema/effusion6
  • burning sensation4
  • injection site pain4
  • asthenia3
  • fatigue3
  • infusion related reaction3
  • discomfort2
  • dizziness2
  • dyspnoea2
  • headache2
  • hyperhidrosis2
  • nausea2

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20151
20237
20242
20256
20265

Recalls

1 FDA enforcement reports for this application.

  • Aug 22, 2023 · Class II · Terminated

    Lack of Assurance of Sterility: out-of-specification test results observed for Filter Integrity Test (FIT).

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1 on PubMed

Sponsor: Lantheus

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.